Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma

Gloria S. Huang, Margrit Juretzka, Giuseppe Ciaravino, Sabine Kohler, Nelson N H Teng

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background. Primary adenocarcinoma of the vulva is a rare entity, and for widely metastatic vulvar adenocarcinoma, no effective treatment has been established. Case. A 65-year-old woman was diagnosed with regionally advanced vulvar adenocarcinoma, with bulky involvement of bilateral groin lymph nodes, and associated extramammary Paget's disease. Initial therapy consisted of multiagent chemotherapy and vulvar and groin irradiation, followed by radical vulvectomy with groin and pelvic lymph node dissection. She subsequently developed widely metastatic disease including brain, pulmonary, hepatic, osseus, and subcutaneous lesions. Treatment with liposomal doxorubicin (Doxil) resulted in dramatic regression of metastatic lesions and marked improvement in quality-of-life. She remains clinically well, greater than 1 year since initiating Doxil treatment for widely metastatic vulvar adenocarcinoma, and has surpassed 5 years of survival since her initial diagnosis. Conclusions. We report the first case of Doxil used for the treatment of metastatic chemorefractory vulvar adenocarcinoma. We observed that Doxil was a well-tolerated and effective agent for this gynecologic malignancy, and warrants further investigation.

Original languageEnglish (US)
Pages (from-to)313-318
Number of pages6
JournalGynecologic Oncology
Volume87
Issue number3
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Adenocarcinoma
Groin
Extramammary Paget's Disease
Therapeutics
Vulva
Brain Diseases
Lymph Node Excision
Lymph Nodes
Quality of Life
liposomal doxorubicin
Drug Therapy
Lung
Survival
Liver
Neoplasms

Keywords

  • Adenocarcinoma
  • Doxorubicin
  • Extramammary Paget's disease
  • Liposome
  • Vulvar neoplasm

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Huang, G. S., Juretzka, M., Ciaravino, G., Kohler, S., & Teng, N. N. H. (2002). Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. Gynecologic Oncology, 87(3), 313-318. https://doi.org/10.1006/gyno.2002.6830

Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. / Huang, Gloria S.; Juretzka, Margrit; Ciaravino, Giuseppe; Kohler, Sabine; Teng, Nelson N H.

In: Gynecologic Oncology, Vol. 87, No. 3, 2002, p. 313-318.

Research output: Contribution to journalArticle

Huang, GS, Juretzka, M, Ciaravino, G, Kohler, S & Teng, NNH 2002, 'Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma', Gynecologic Oncology, vol. 87, no. 3, pp. 313-318. https://doi.org/10.1006/gyno.2002.6830
Huang, Gloria S. ; Juretzka, Margrit ; Ciaravino, Giuseppe ; Kohler, Sabine ; Teng, Nelson N H. / Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma. In: Gynecologic Oncology. 2002 ; Vol. 87, No. 3. pp. 313-318.
@article{924cc53ce10b4e7f81e4570a59f75e19,
title = "Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma",
abstract = "Background. Primary adenocarcinoma of the vulva is a rare entity, and for widely metastatic vulvar adenocarcinoma, no effective treatment has been established. Case. A 65-year-old woman was diagnosed with regionally advanced vulvar adenocarcinoma, with bulky involvement of bilateral groin lymph nodes, and associated extramammary Paget's disease. Initial therapy consisted of multiagent chemotherapy and vulvar and groin irradiation, followed by radical vulvectomy with groin and pelvic lymph node dissection. She subsequently developed widely metastatic disease including brain, pulmonary, hepatic, osseus, and subcutaneous lesions. Treatment with liposomal doxorubicin (Doxil) resulted in dramatic regression of metastatic lesions and marked improvement in quality-of-life. She remains clinically well, greater than 1 year since initiating Doxil treatment for widely metastatic vulvar adenocarcinoma, and has surpassed 5 years of survival since her initial diagnosis. Conclusions. We report the first case of Doxil used for the treatment of metastatic chemorefractory vulvar adenocarcinoma. We observed that Doxil was a well-tolerated and effective agent for this gynecologic malignancy, and warrants further investigation.",
keywords = "Adenocarcinoma, Doxorubicin, Extramammary Paget's disease, Liposome, Vulvar neoplasm",
author = "Huang, {Gloria S.} and Margrit Juretzka and Giuseppe Ciaravino and Sabine Kohler and Teng, {Nelson N H}",
year = "2002",
doi = "10.1006/gyno.2002.6830",
language = "English (US)",
volume = "87",
pages = "313--318",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Liposomal doxorubicin for treatment of metastatic chemorefractory vulvar adenocarcinoma

AU - Huang, Gloria S.

AU - Juretzka, Margrit

AU - Ciaravino, Giuseppe

AU - Kohler, Sabine

AU - Teng, Nelson N H

PY - 2002

Y1 - 2002

N2 - Background. Primary adenocarcinoma of the vulva is a rare entity, and for widely metastatic vulvar adenocarcinoma, no effective treatment has been established. Case. A 65-year-old woman was diagnosed with regionally advanced vulvar adenocarcinoma, with bulky involvement of bilateral groin lymph nodes, and associated extramammary Paget's disease. Initial therapy consisted of multiagent chemotherapy and vulvar and groin irradiation, followed by radical vulvectomy with groin and pelvic lymph node dissection. She subsequently developed widely metastatic disease including brain, pulmonary, hepatic, osseus, and subcutaneous lesions. Treatment with liposomal doxorubicin (Doxil) resulted in dramatic regression of metastatic lesions and marked improvement in quality-of-life. She remains clinically well, greater than 1 year since initiating Doxil treatment for widely metastatic vulvar adenocarcinoma, and has surpassed 5 years of survival since her initial diagnosis. Conclusions. We report the first case of Doxil used for the treatment of metastatic chemorefractory vulvar adenocarcinoma. We observed that Doxil was a well-tolerated and effective agent for this gynecologic malignancy, and warrants further investigation.

AB - Background. Primary adenocarcinoma of the vulva is a rare entity, and for widely metastatic vulvar adenocarcinoma, no effective treatment has been established. Case. A 65-year-old woman was diagnosed with regionally advanced vulvar adenocarcinoma, with bulky involvement of bilateral groin lymph nodes, and associated extramammary Paget's disease. Initial therapy consisted of multiagent chemotherapy and vulvar and groin irradiation, followed by radical vulvectomy with groin and pelvic lymph node dissection. She subsequently developed widely metastatic disease including brain, pulmonary, hepatic, osseus, and subcutaneous lesions. Treatment with liposomal doxorubicin (Doxil) resulted in dramatic regression of metastatic lesions and marked improvement in quality-of-life. She remains clinically well, greater than 1 year since initiating Doxil treatment for widely metastatic vulvar adenocarcinoma, and has surpassed 5 years of survival since her initial diagnosis. Conclusions. We report the first case of Doxil used for the treatment of metastatic chemorefractory vulvar adenocarcinoma. We observed that Doxil was a well-tolerated and effective agent for this gynecologic malignancy, and warrants further investigation.

KW - Adenocarcinoma

KW - Doxorubicin

KW - Extramammary Paget's disease

KW - Liposome

KW - Vulvar neoplasm

UR - http://www.scopus.com/inward/record.url?scp=0036928246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036928246&partnerID=8YFLogxK

U2 - 10.1006/gyno.2002.6830

DO - 10.1006/gyno.2002.6830

M3 - Article

C2 - 12468332

AN - SCOPUS:0036928246

VL - 87

SP - 313

EP - 318

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -